Announcements Trials

Browse Landscape

Phase

Phase 1 14 Phase 2 13 Phase 1/2 5 Phase NA 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 92 Recurrence 12 Neoplasms, Plasma Cell 10 Immunoglobulin Light-chain Amyloidosis 6 Paraproteinemias 4 Neoplasms 4 Amyloidosis 3 Lymphoproliferative Disorders 2 Lymphoma, Mantle-Cell 2 Immunoproliferative Disorders 2 Hematologic Diseases 2 Disease Progression 2 Waldenstrom Macroglobulinemia 1 Vascular Diseases 1 Sezary Syndrome 1 Sarcoma, Myeloid 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Plasmacytoma 1 Peripheral Nervous System Diseases 1 Pathologic Complete Response 1 Neoplasms by Histologic Type 1 Mycosis Fungoides 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Immune System Diseases 1

Interventions

Rituximab 66 Cyclophosphamide 46 Vincristine 40 Doxorubicin 40 Prednisone 35 Etoposide 19 Radiotherapy 14 Gemcitabine 13 Peripheral Blood Stem Cell Transplantation 12 Filgrastim 12 Cytarabine 12 Lenalidomide 11 Carmustine 10 VAP-cyclo protocol 9 Prednisolone 9 Oxaliplatin 9 Melphalan 9 Methotrexate 7 Ifosfamide 7 Mitoxantrone 6 Bleomycin 6 polatuzumab vedotin 5 R-CHOP protocol 4 Methylprednisolone 4 Injections 4 Granulocyte Colony-Stimulating Factor 4 Cyclosporine 4 Cisplatin 4 Carboplatin 4 pegfilgrastim 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lymphoma, Large B-Cell, Diffuse × Bortezomib × Clear all

NCT01324596 2016-04-15

REMoDL-B

University Hospital Southampton NHS Foundation Trust

Phase 3 Completed

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡